ReviewBone2017
Hormonal and systemic regulation of sclerostin.
Review in Bone, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 77 citations in OpenAlex.
- Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.Nature medicine · 2024Trial
- Effects of progesterone therapy on serum sclerostin levels in healthy menopausal women: a 3-month randomized, placebo-controlled clinical trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2020Trial
- Sclerostin and parathyroid hormone responses to acute whole-body vibration and resistance exercise in young women.Journal of bone and mineral metabolism · 2019Trial
- Relationship between bone resorption and sclerostin regulation in apical periodontitis lesions.Odontology · 2026Article
- Sclerostin's role in bone-muscle crosstalk and osteoporosis pathogenesis.Osteoporosis and sarcopenia · 2025Review
- Induction of osteoblast apoptosis stimulates macrophage efferocytosis and paradoxical bone formation.Bone research · 2024Article
- Sclerostin and Wnt Signaling in Idiopathic Juvenile Osteoporosis Using High-Resolution Confocal Microscopy for Three-Dimensional Analyses.Children (Basel, Switzerland) · 2024Article
- 17β-Estradiol (E2) Activates Matrix Mineralization through Genomic/Nongenomic Pathways in MC3T3-E1 Cells.International journal of molecular sciences · 2024Article
- Evaluation of Trabecular Bone Microarchitecture and Bone Mineral Density in Young Women, Including Selected Hormonal Parameters.Biomedicines · 2024Article
- The hidden cross talk between bone and tissues through bone turnover.Advances in laboratory medicine · 2024Article
- Article
- Article
- Common Regulators of Lipid Metabolism and Bone Marrow Adiposity in Postmenopausal Women.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Sclerostin decreases in regular swimmers after ice swimming and is associated with meteorin-like protein serum levels.Frontiers in physiology · 2023Article
- Editorial: Crosstalk between bone and other cells.Frontiers in physiology · 2023Article
- Sclerostin in Excessive Drinkers: Relationships with Liver Function and Body Composition.Nutrients · 2022Article
- Serum Sclerostin and Its Association with Bone Turnover Marker in Metabolic Bone Diseases.Disease markers · 2022Article
- Low sclerostin levels after long-term remission of acromegaly.Endocrine · 2022Article
- Gestational and lactational exposure to BPA, but not BPS, negatively impacts trabecular microarchitecture and cortical geometry in adult male offspring.Bone reports · 2021Article
- Gestational and lactational exposure to BPA or BPS has minimal effects on skeletal outcomes in adult female mice.Bone reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The Wnt/β-catenin signaling pathway plays an essential role in osteoblast biology. Sclerostin is a soluble antagonist of Wnt/β-catenin signaling secreted primarily by osteocytes. Current evidence indicates that sclerostin likely functions as a local/paracrine regulator of bone metabolism rather than as an endocrine hormone. Nonetheless, circulating sclerostin levels in humans often reflect changes in the bone microenvironment, although there may be exceptions to this observation. Using existing assays, circulating sclerostin levels have been shown to be altered in response to both hormonal stimuli and across a variety of normal physiological and pathophysiological conditions. In both rodents and humans, parathyroid hormone provided either intermittently or continuously suppresses sclerostin levels. Likewise, most evidence from both human and animal studies supports a suppressive effect of estrogen on sclerostin levels. Efforts to examine non-hormonal/systemic regulation of sclerostin have in general shown less consistent findings or have provided associations rather than direct interventional information, with the exception of mechanosensory studies which have consistently demonstrated increased sclerostin levels with skeletal unloading, and conversely decreases in sclerostin with enhanced skeletal loading. Herein, we will review the existent literature on both hormonal and non-hormonal/systemic factors which have been studied for their impact on sclerostin regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.